Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us 
About
Not Confirmed
Not Confirmed
10-14 May, 2026
Gynecology and Obstetr...Gynecology and Obstetrics
Not Confirmed
Not Confirmed
11-12 May, 2026
PEGS Boston SummitPEGS Boston Summit
Not Confirmed
Not Confirmed
11 May-15 November, 2026
List your booth number for exhibitions, ask us 
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
RDD
Not Confirmed
Contact SupplierRDD
Industry Trade Show
Not Confirmed
10-14 May, 2026
Gynecology and Obstetr...Gynecology and Obstetrics
Industry Trade Show
Not Confirmed
11-12 May, 2026
PEGS Boston SummitPEGS Boston Summit
Industry Trade Show
Not Confirmed
11 May-15 November, 2026
Digital content
NEWS #PharmaBuzz
30 Apr 2026
// PRESS RELEASE
30 Mar 2026
// BUSINESSWIRE
https://www.businesswire.com/news/home/20260330646991/en/Prilenia-and-Ferrer-Announce-First-Participant-Enrolled-in-the-PREVAiLS-Phase-3-Study-of-Pridopidine-in-ALS
30 Mar 2026
// PRESS RELEASE
https://www.ferrer.com/en/Ferrer-and-Prilenia-Announce-First-Participant-Enrolled-in-the-PREVAiLS-Phase-3-Study-of-Pridopidine-in-ALS
18 Mar 2026
// PHARMIWEB
https://www.pharmiweb.com/press-release/2026-03-18/ferrer-included-in-the-ranking-of-the-world-s-most-ethical-companies-in-2026
11 Dec 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20251211232354/en/Prilenia-and-Ferrer-Announce-FDA-Clearance-to-Start-the-PREVAiLS-Pivotal-Phase-3-Study-with-Pridopidine-in-ALS
21 Oct 2025
// PRESS RELEASE
https://www.ferrer.com/en/Ferrer-completes-recruitment-of-220-patients-for-the-prosper-study-a-phase-ii-clinical-trial-in-progressive-supranuclear-palsy-psp-two-months-ahead-of-schedule
Drugs in Development
Details:
Pridopidine is a Small Molecule drug, which is currently being evaluated in Phase III clinical studies for the treatment of Amyotrophic Lateral Sclerosis.
Lead Product(s): Pridopidine
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Recipient: Prilenia therapeutics
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 07, 2026
Lead Product(s) : Pridopidine
Therapeutic Area : Neurology
Highest Development Status : Phase III
Recipient : Prilenia therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS (NCT07322003 DU)
Details : Pridopidine is a Small Molecule drug, which is currently being evaluated in Phase III clinical studies for the treatment of Amyotrophic Lateral Sclerosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 07, 2026
Details:
Under the licensing agreement, Ferrer will holds the right to develop TV-7820 (pridopidine) an orally administered sigma-1 receptor agonist. It is being evaluated for Huntington’s Disease.
Lead Product(s): Pridopidine
Therapeutic Area: Genetic Disease Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Recipient: Prilenia therapeutics
Deal Size: $568.0 million Upfront Cash: $90.8 million
Deal Type: Licensing Agreement April 28, 2025
Lead Product(s) : Pridopidine
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Recipient : Prilenia therapeutics
Deal Size : $568.0 million
Deal Type : Licensing Agreement
Ferrer and Prilenia Partner for Pridopidine Commercialization and Co-Development (29422 D)
Details : Under the licensing agreement, Ferrer will holds the right to develop TV-7820 (pridopidine) an orally administered sigma-1 receptor agonist. It is being evaluated for Huntington’s Disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : $90.8 million
April 28, 2025
Details:
FNP-223 is a small molecule oral tablet, which is being evaluated in the mid-stage clinical trial studies to slow the progression of Progressive Supranuclear Palsy.
Lead Product(s): FNP-223
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 17, 2024
Ferrer Advances Research on Progressive Supranuclear Palsy with Phase II (46074 DU)
Details : FNP-223 is a small molecule oral tablet, which is being evaluated in the mid-stage clinical trial studies to slow the progression of Progressive Supranuclear Palsy.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 17, 2024
Details:
FNP-223 is an orally administered small molecule drug candidate, which is currently being evaluated for the treatment of progressive supranuclear palsy.
Lead Product(s): FNP-223
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 12, 2024
Details : FNP-223 is an orally administered small molecule drug candidate, which is currently being evaluated for the treatment of progressive supranuclear palsy.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 12, 2024
Details:
The agreement aims for the distribution of Tyvaso (treprostinil inhalation solution), a drug-device combination authorized for the treatment of WHO Group 3 PH-ILD.
Lead Product(s): Treprostinil Sodium
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Tyvaso
Study Phase: Approved FDFProduct Type: Miscellaneous
Recipient: United Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 27, 2024
Lead Product(s) : Treprostinil Sodium
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved FDF
Recipient : United Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Ferrer Obtains the Distribution Rights of a Potential Treatment for IPF and PPF (27530 D)
Details : The agreement aims for the distribution of Tyvaso (treprostinil inhalation solution), a drug-device combination authorized for the treatment of WHO Group 3 PH-ILD.
Product Name : Tyvaso
Product Type : Miscellaneous
Upfront Cash : Undisclosed
May 27, 2024
Details:
FNP-223 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Supranuclear Palsy, Progressive.
Lead Product(s): FNP-223
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 09, 2024
Details : FNP-223 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Supranuclear Palsy, Progressive.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 09, 2024
Details:
The collaboration aims to co-develop VRG50635, Verge’s potent PIKfyve inhibitor, for treating sporadic & familial amyotrophic lateral sclerosis in various regions, including Europe & Southeast Asia.
Lead Product(s): VRG50635
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Recipient: Verge Genomics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 25, 2024
Lead Product(s) : VRG50635
Therapeutic Area : Neurology
Highest Development Status : Phase I
Recipient : Verge Genomics
Deal Size : Undisclosed
Deal Type : Collaboration
Verge Genomics Partners with Ferrer To Co-Develop ALS Therapy VRG50635 (25267 D)
Details : The collaboration aims to co-develop VRG50635, Verge’s potent PIKfyve inhibitor, for treating sporadic & familial amyotrophic lateral sclerosis in various regions, including Europe & Southeast Asia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
March 25, 2024
Details:
FAB122 (edaravone) is an investigational once daily, oral, small molecule drug candidate, which is currently being evaluated for the treatment of amyotrophic lateral sclerosis.
Lead Product(s): Edaravone
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 10, 2024
Ferrer Reports Top-Line Results from Phase III ADORE Study in ALS (46452 DU)
Details : FAB122 (edaravone) is an investigational once daily, oral, small molecule drug candidate, which is currently being evaluated for the treatment of amyotrophic lateral sclerosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 10, 2024
Details:
FAB122 (edaravone) is an investigational once daily, oral, small molecule drug candidate, which is currently being evaluated for the treatment of amyotrophic lateral sclerosis.
Lead Product(s): Edaravone
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 22, 2023
Ferrer Extends their Clinical Study in Amyotrophic Lateral Sclerosis (ALS) (46451 DU)
Details : FAB122 (edaravone) is an investigational once daily, oral, small molecule drug candidate, which is currently being evaluated for the treatment of amyotrophic lateral sclerosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 22, 2023
Details:
FAB122 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Amyotrophic Lateral Sclerosis.
Lead Product(s): FAB122
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Undisclosed
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 19, 2023
Details : FAB122 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Amyotrophic Lateral Sclerosis.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
May 19, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Inspections and registrations
ABOUT THIS PAGE
Share 
